The new US Food and Drug Administration commissioner has outlined his top priorities for the agency, including the use of data and patient input to guide regulatory decisions, and feedback from staff on how to improve the agency.
In Letter To FDA Staff, Hahn Lays Out His Cards
In an all-hands email to US FDA staff on 30 January, the new commissioner outlined his top priorities for the agency, including focusing on data when reviewing medical products, getting more feedback from patients and consumers, and finding ways to make the agency more efficient.
More from Regulation
• By
A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.
• By
Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.
• By
As the EU Life Sciences Strategy aims to drive innovation, the medtech sector is pushing for a pivotal role in a mission intended to embrace green and digital transitions, address regulatory obstacles and reduce dependency on external sources.
• By
The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.